Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Hematology & Oncology
Published in: Journal of Hematology & Oncology 1/2013

Open Access 01-12-2013 | Review

Role of platelet chemokines, PF-4 and CTAP-III, in cancer biology

Authors: Katerina Pilatova, Kristina Greplova, Regina Demlova, Beatrix Bencsikova, Giannoula Lakka Klement, Lenka Zdrazilova-Dubska

Published in: Journal of Hematology & Oncology | Issue 1/2013

Login to get access

Abstract

With the recent addition of anti-angiogenic agents to cancer treatment, the angiogenesis regulators in platelets are gaining importance. Platelet factor 4 (PF-4/CXCL4) and Connective tissue activating peptide III (CTAP-III) are two platelet-associated chemokines that modulate tumor angiogenesis, inflammation within the tumor microenvironment, and in turn tumor growth. Here, we review the role of PF-4 and CTAP-III in the regulation of tumor angiogenesis; the results of clinical trial using recombinant PF-4 (rPF-4); and the use of PF-4 and CTAP-III as cancer biomarkers.
Appendix
Available only for authorised users
Literature
1.
Klement GL, Yip TT, Cassiola F, Kukuchi L, Cervi D, Podust V, Italiano JE, Wheatley E, Abou-Slaybi A, Bender E, Almog N, Kieran MW, Folkman J: Platelets actively sequester angiogenesis regulators. Blood. 2009, 130: 2835-2842.CrossRef
2.
Von Hundelshausen P, Petersen F, Brandt E: Platelet-derived chemokines in vascular biology. Thromb Haemost. 2007, 97: 704-713.PubMed
3.
Belperio JA, Keane MP, Arenberg DA, Addison CL, Ehlert JE, Burdick MD, Strieter RM: CXC chemokines in angiogenesis. J Leukoc Biol. 2000, 68: 1-8.PubMed
4.
Fivenson DP, Faria DT, Nickoloff BJ, Poverini PJ, Kunkel S, Burdick M, Strieter RM: Chemokine and inflammatory cytokine changes during chronic wound healing. Wound Repair Regen. 1997, 5: 310-322. 10.1046/j.1524-475X.1997.50405.x.CrossRefPubMed
5.
Strieter RM, Polverini PJ, Kunkel SL: The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J Biol Chem. 1995, 270: 27348-27357. 10.1074/jbc.270.45.27348.CrossRefPubMed
6.
Deuel TF, Keim PS, Farmer M, Heinrikson RL: Amino acid sequence of human platelet factor 4. Proc Natl Acad Sci USA. 1977, 74: 2256-2258. 10.1073/pnas.74.6.2256.PubMedCentralCrossRefPubMed
7.
Tunnaclife A, Majumdar S, Yan B, Poncz M: Genes for beta-thromboglobulin and platelet factor 4 are closely linked and form part of a cluster of related genes on chromosome 4. Blood. 1992, 79: 2896-2900.
8.
Ryo R, Nakeff A, Huang SS, Ginsberg M, Deuel TF: New synthesis of a platelet-specific protein: platelet factor 4 synthesis in a megakaryocyte-enriched rabbit bone marrow culture system. J Cell Biol. 1983, 96: 515-520. 10.1083/jcb.96.2.515.CrossRefPubMed
9.
Barber AJ, Käser-Glanzmann R, Jakábová M, Luscher EF: Characterization of a chondroitin 4-sulfate proteoglycan carrier for heparin neutralizing activity (platelet factor 4) released from human blood platelets. Biochem Biophys Acta. 1972, 286: 312-329. 10.1016/0304-4165(72)90267-X.CrossRefPubMed
10.
Peterson JE, Zurakowski D, Italiano JE, Michel LV, Fox L, Klement GL, Folkman J: Normal ranges of angiogenesis regulatory proteins in human platelets. Am J Hematol. 2010, 85: 487-493. 10.1002/ajh.21732.CrossRefPubMed
11.
Zucker B, Katz R: Platelet factor 4: production, structure, and physiologic and immunologic action. Proc Soc Exp Biol Med. 1991, 198: 693-702. 10.3181/00379727-198-43309.CrossRefPubMed
12.
Kaper B, Petersen F: Molecular pathways of platelet factor 4/CXCL4 signaling. Eur J Cell Biol. 2011, 90: 521-526. 10.1016/j.ejcb.2010.12.002.CrossRef
13.
Files JC, Malpass TW, Yee EK, Ritchie JL, Harker LA: Studies of human plate alpha-granule release in vivo. Blood. 1981, 58: 607-618.PubMed
14.
Gerotziafas GT, Elalamy I, Lecrubier C, Lebrazi J, Mirshahi M, Potevin F, Lecompte T, Samama MM: The role of platelet factor 4 in platelet aggregation induced by the antibodies implicated in heparin-induced thrombocytopenia. Blood Coagul Fibrinolysis. 2001, 12: 511-520. 10.1097/00001721-200110000-00002.CrossRefPubMed
15.
Piepkorn MW: Dansyl (5-dimethylaminonaphthalene-1-sulphonyl)-heparin binds antithrombin III and platelet factor 4 at separate sites. Biochem J. 1981, 196: 649-651.PubMedCentralCrossRefPubMed
16.
Dumenco LL, Everson B, Culp LA, Ratnoff OD: Inhibition of the activation of Hageman factor (factor XII) by platelet factor 4. J Lab Clin Med. 1988, 112: 394-400.PubMed
17.
Yang L, Rezaie AR: Calcium-binding sites of the thrombin-thrombomodulin-protein C complex: possible implications for the effect of platelet factor 4 on the activation of vitamin K-dependent coagulation factors. Thromb Haemost. 2007, 97: 899-906.PubMed
18.
Slungaard A, Fernandez JA, Griffin JH, Key NS, Long JR, Piegors DJ, Lentz SR: Platelet factor 4 enhances generation of activated protein C in vitro and in vivo. Blood. 2003, 102: 146-151. 10.1182/blood-2002-11-3529.CrossRefPubMed
19.
Han ZC, Bellucci S, Walz A, Baggiolini M, Caen JP: Negative regulation of human megakaryocytopoiesis by human platelet factor 4 (PF4) and connective tissue-activating peptide (CTAP-III). Int J Cell Cloning. 1990, 8: 253-259. 10.1002/stem.5530080409.CrossRefPubMed
20.
Han ZC, Sensébe L, Abgrall JF, Brière J: Platelet factor 4 inhibits human megakaryocytopoiesis in vitro. Blood. 1990, 75: 1234-1239.PubMed
21.
Lambert MP, Rauova L, Bailey M, Sola-Visner MC, Kowalska MA, Poncz M: Platelet factor 4 is a negative autocrine in vivo regulator of megakaryopoiesis: clinical and therapeutic implications. Blood. 2007, 110: 1153-1160. 10.1182/blood-2007-01-067116.PubMedCentralCrossRefPubMed
22.
Lambert MP, Wang Y, Bdeir KH, Nguyen Y, Kowalska MA, Poncz M: Platelet factor 4 regulates megakaryopoiesis through low-density lipoprotein receptor-related protein 1 (LRP1) on megakaryocytes. Blood. 2009, 114: 2290-2298. 10.1182/blood-2009-04-216473.PubMedCentralCrossRefPubMed
23.
Lambert MP, Xiao L, Nguyen Y, Kowalska MA, Poncz M: The role of platelet factor 4 in radiation-induced thrombocytopenia. Int J Radiat Oncol Biol Phys. 2011, 80: 1533-1540. 10.1016/j.ijrobp.2011.03.039.PubMedCentralCrossRefPubMed
24.
Lecomte-Raclet L, Alemany M, Sequeira-Le Grand A, Amiral J, Quentin G, Vissac AM, Caen JP, Han ZC: New insights into the negative regulation of hematopoiesis by chemokine platelet factor 4 and related peptides. Blood. 1998, 91: 2772-2780.PubMed
25.
Dudek AZ, Nesmelova I, Mayo K, Verfaillie CM, Pitchford S, Slungaard A: Platelet factor 4 promotes adhesion of hematopoietic progenitor cells and binds IL-8: novel mechanisms for modulation of hematopoiesis. Blood. 2003, 101: 4687-4694. 10.1182/blood-2002-08-2363.CrossRefPubMed
26.
Castor CW, Miller JW, Walz DA: Structural and biological characteristics of connective tissue activating peptide (CTAP-III), a major human platelet-derived growth factor. Cell Biol. 1983, 80: 765-769.
27.
El-Gedaily A, Schoedon G, Schneemann M, Schaffner A: Constitutive and regulated expression of platelet basic protein in human monocytes. J Leukoc Biol. 2004, 75: 495-503.CrossRefPubMed
28.
Lida N, Haisa M, Igarashi A, Pencev D, Grotendorst GR: Leukocyte-derived growth factor links the PDGF and CXC chemokine families of peptides. FASEB J. 1996, 10: 1336-1345.
29.
Deutsch V, Bitan M, Friedmann Y, Eldor A, Vlodavsky I: Megakaryocyte maturation is associated with expression of the CXC chemokine connective tissue-activating peptide CTAP III. Br J Haematol. 2000, 111: 1180-1189. 10.1046/j.1365-2141.2000.02476.x.CrossRefPubMed
30.
Resmi KR, Krishnan LK: Protease action and generation of beta-thromboglobulin-like protein followed by platelet activation. Thromb Res. 2002, 106: 229-236. 10.1016/S0049-3848(02)00135-4.CrossRefPubMed
31.
Schiemann F, Grimm TA, Hoch J, Gross R, Lindner B, Petersen F, Bulfone-Paus S, Brandt E: Mast cells and neutrophils proteolytically activate chemokine precursor CTAP-III and are subject to counterregulation by PF-4 through inhibition of chymase and cathepsin G. Blood. 2006, 107: 2234-2242. 10.1182/blood-2005-06-2424.CrossRefPubMed
32.
Walz A, Baggioloni M: Generation of the neutrophil-activating peptide NAP-2 from platelet basic protein or connective tissue-activating peptide III through monocyte proteases. J Exp Med. 1990, 171: 449-454. 10.1084/jem.171.2.449.CrossRefPubMed
33.
Walz A, Dewald B, von Tscharner V, Baggiolini M: Effects of the neutrophil-activating peptide NAP-2, platelet basic protein, connective tissue-activating peptide III and platelet factor 4 on human neutrophils. J Exp Med. 1989, 170: 1745-1750. 10.1084/jem.170.5.1745.CrossRefPubMed
34.
Castor CW, Ritchie JC, Williams CH, Scott ME, Whitney SL, Myers SL, Sloan TB, Anderson BE: Connective tissue activation. XIV. Composition and actions of a human platelet autacoid mediator. Arthritis Rheum. 1979, 22: 260-272. 10.1002/art.1780220308.CrossRefPubMed
35.
Ragsdale CG, Castor CW, Roberts DJ, Swartz KH: Connective tissue activating peptide III. Induction of synthesis and secretion of plasminogen activator by synovial fibroblasts. Arthritis Rheum. 1984, 27: 663-667. 10.1002/art.1780270609.CrossRefPubMed
36.
Brandt E, Petersen F, Ludwig A, Ehlert JE, Bock L, Flad HD: The beta-thromboglobulins and platelet factor 4: blood platelet derived CXC chemokines with divergent roles in early neutrophil regulation. J Leukoc Biol. 2000, 67: 471-478.PubMed
37.
Proudfoot AE, Peitsch MC, Power CA, Allet B, Mermod JJ, Bacon K, Wells TN: Structure and bioactivity of recombinant human CTAP-III and NAP-2. J Protein Chem. 1997, 16: 37-49. 10.1023/A:1026390811336.CrossRefPubMed
38.
Tai PK, Liao JF, Hossler PA, Castor CW, Carter-Su C: Regulation of glucose transporters by connective tissue activating peptide-III isoforms. J Biol Chem. 1992, 267: 19579-19586.PubMed
39.
Stoeckelhuber M, Dobner P, Baumgärtner P, Ehlert J, Brandt E, Mentele R, Adam D, Engelmann B: Stimulation of cellular sphingomyelin import by the chemokine connective tissue-activating peptide III. J Biol Chem. 2000, 275: 37365-37372. 10.1074/jbc.M003709200.CrossRefPubMed
40.
Hoogewerf AJ, Leone JW, Reardon IM, Howe WJ, Asa D, Heinrikson RL, Ledbetter SR: CXC chemokines connective tissue activating peptide-III and neutrophil activating peptide-2 are heparin/heaparan sulfate-degrading enzymes. J Biol Chem. 1995, 7: 3268-3277.
41.
Pandya NM, Dhalla NS, Santani DD: Angiogenesis—a new target for future therapy. Vascul Pharmacol. 2006, 44: 265-274. 10.1016/j.vph.2006.01.005.CrossRefPubMed
42.
Gasic GJ, Gasic TB, Stewart CC: Antimetastatic effects associated with platelet reduction. Proc Natl Acad Sci USA. 1968, 61: 46-52. 10.1073/pnas.61.1.46.PubMedCentralCrossRefPubMed
43.
Karpatkin S, Ambrogio C, Pearlstein E: The role of tumor-induced platelet aggregation, platelet adhesion and adhesive proteins in tumor metastasis. Prog Clin Biol Res. 1988, 283: 585-606.PubMed
44.
Pinedo HM, Verheul HM, D’Amato RJ, Folkman J: Involvement of platelets in tumour angiogenesis?. Lancet. 1998, 352: 1775-1777. 10.1016/S0140-6736(98)05095-8.CrossRefPubMed
45.
Gay LJ, Felding-Habermann B: Contribution of platelets to tumour metastasis. Nat Rev Cancer. 2011, 11: 123-134. 10.1038/nrc3004.CrossRefPubMed
46.
Italiano JE, Richardson JL, Patel-Hett S, Battinelli E, Zaslavsky A, Short S, Ryeom S, Folkman J, Klement GL: Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate α-granules and differentially released. Blood. 2008, 111: 1227-1233.PubMedCentralCrossRefPubMed
47.
Perollet C, Han ZC, Savona C, Caen JP, Bikfalvi A: Platelet factor-4 modulates fibroblast growth factor 2 (FGF2) activity and inhibits FGF2 dimerization. Blood. 1998, 91: 3289-3299.PubMed
48.
Gengrinowitch S, Greenberg SM, Cohen T, Gitay-Goren H, Rockwell P, Maione TE, Levi BZ, Neufeld G: Platelet factor-4 inhibits the mitogenic activity of VEGF121 and VEGF165 using several concurrent mechanisms. J Biol Chem. 1995, 270: 15059-15065. 10.1074/jbc.270.25.15059.CrossRef
49.
Nesmelova IV, Sham Y, Dudek AZ, van Eijk LI, Wu G, Slungaard A, Mortari F, Griffioen AW, Mayo KH: Platelet factor 4 and interleukin-8 CXC chemokine heterodimer formation modulates function at the quaternary structural level. J Biol Chem. 2005, 280: 4948-4958.CrossRefPubMed
50.
Jones SA, Dewald B, Clark-Lewis I, Baggiolini M: Chemokine antagonists that discriminate between interleukin-8 receptors. Selective blockers of CXCR2. J Biol Chem. 1997, 272: 16166-16169. 10.1074/jbc.272.26.16166.CrossRefPubMed
51.
Ehlert JE, Ludwig A, Grimm GA, Lindner B, Flad HD, Brandt E: Down-regulation of neutrophil functions by the ELR(+) CXC chemokine platelet basic protein. Blood. 2000, 96: 2965-2972.PubMed
52.
Li A, Dubey S, Varney ML, Dave BJ, Singh RK: IL-8 directly enhances endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. J Immunol. 2003, 170: 3369-3376.CrossRefPubMed
53.
Tang Z, Yu M, Miller F, Berk RS, Tromp G, Kosir MA: Increased invasion through basement membrane by CXCL7-transfected breast cells. Am J Surg. 2008, 196: 690-696. 10.1016/j.amjsurg.2008.08.001.CrossRefPubMed
54.
Castor CW, Whitney SL: Connective tissue activation. XIII. Stimulation of sulfated glycosaminoglycans synthesis in human connective tissue cells by peptide mediators from lymphocytes and platelets. J Lab Clin Med. 1978, 91: 811-821.PubMed
55.
Hristov M, Zernecke A, Bidzhekov K, Liehn EA, Shagdarsuren E, Ludwig A, Weber C: Importance of CXC chemokine receptor 2 in the homing of human peripheral blood endothelial progenitor cells to sites of arterial injury. Circ Res. 2007, 100: 590-597. 10.1161/01.RES.0000259043.42571.68.CrossRefPubMed
56.
Grupta SK, Singh JP: Inhibition of endothelial cell proliferation by platelet factor-4 involves a unique action on S phase progression. J Cell Biol. 1994, 127: 1121-1127. 10.1083/jcb.127.4.1121.CrossRef
57.
Yang L, Du J, Hou J, Jiang H, Zou J: Platelet factor-4 and its p17-70 peptide inhibit myeloma proliferation and angiogenesis in vivo. BMC Cancer. 2011, 11: s261-10.1186/1471-2407-11-261.CrossRef
58.
Jouan V, Canron X, Alemany M, Caen JP, Quentin G, Plouet J, Bikfalvi A: Inhibition of in vitro angiogenesis by platelet factor-4-derived peptides and mechanism of action. Blood. 1999, 94: 984-993.PubMed
59.
Maione TE, Gray GS, Petro J, Hunt AJ, Donner AL, Bauer SI, Carson HF, Sharpe RJ: Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. Science. 1990, 247: 77-79. 10.1126/science.1688470.CrossRefPubMed
60.
Chadderton NS, Stringer SE: Interaction of platelet factor 4 with fibroblast growth factor 2 is stabilised by heparan sulphate. Int J Biochem Cell Biol. 2003, 35: 1052-1055. 10.1016/S1357-2725(02)00299-6.CrossRefPubMed
61.
Lozano RM, Redondo-Horcajo M, Jiménez MÁ, Zilberberg L, Cuevas P, Bikfalvi A, Rico M, Giménez-Gallego G: Solution structure and interaction with basic and acidic fibroblast growth factor of a 3-kDa human platelet factor-4 fragment with antiangiogenic aktivity. J Biol Chem. 2001, 276: 35723-35734. 10.1074/jbc.M101565200.CrossRefPubMed
62.
Lasagni L, Francalanci M, Annunziato F, Lazzeri E, Giannini S, Cosmi L, Sagrinati C, Mazzinghi B, Orlando C, Maggi E, Marra F, Romagnani S, Serio M, Romagnani P: An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4. J Exp Med. 2003, 197: 1537-1549. 10.1084/jem.20021897.PubMedCentralCrossRefPubMed
63.
Struyf S, Sologni L, Burdick MD, Vandercappellen J, Gouwy M, Noppen S, Proost P, Opdenakker G, Parmentier M, Gerard C, Sozzani S, Strieter RM, Van Damme J: Angiostatic and chemotactic activities of the CXC chemokine CXCL4L1 (platelet factor-4 variant) are mediated by CXCR3. Blood. 2011, 117: 480-488. 10.1182/blood-2009-11-253591.PubMedCentralCrossRefPubMed
64.
Woller G, Brandt E, Mittelstädt J, Rybakowski C, Petersen F: Platelet factor 4/CXCL4-stimulated human monocytes induce apoptosis in endothelial cells by the release of oxygen radicals. J Leukoc Biol. 2008, 83: 936-945. 10.1189/jlb.0907592.CrossRefPubMed
65.
Vandercappellen J, Van Damme J, Struyf S: The role of the CXC chemokines platelet factor-4 (CXCL4/PF-4) and its variant (CXCL4L1/PF-4var) in inflammation, angiogenesis and cancer. Cytokine Growth Factor Rev. 2011, 22: 1-18. 10.1016/j.cytogfr.2010.10.011.CrossRefPubMed
66.
Sharpe RJ, Byers HR, Scott CF, Bauer SI, Maione TE: Growth inhibition of murine melanoma and human colon carcinoma by recombinant human platelet factor 4. J Natl Cancer Inst. 1990, 82: 848-853. 10.1093/jnci/82.10.848.CrossRefPubMed
67.
Kolber DL, Knisely TL, Malone TE: Inhibition of development of murine melanoma lung metastases by systemic administration of recombinant platelet factor 4. J Natl Cancer Inst. 1995, 15: 304-309.CrossRef
68.
Tanaka T, Manome Y, Wen P, Kufe DW, Fine HA: Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth. Nat Med. 1997, 3: 437-442. 10.1038/nm0497-437.CrossRefPubMed
69.
Yamaguchi K, Ogawa K, Katsube T, Shimao K, Konno S, Shimakawa T, Yoshimatsu K, Naritaka Y, Yagawa H, Hirose K: Platelet factor 4 gene transfection into tumor cells inhibits angiogenesis, tumor growth and metastasis. Anticancer Res. 2005, 25: 847-852.PubMed
70.
Noonan DM, De Lerma Barbaro A, Vannini N, Mortara L, Albini A: Inflammation, inflammatory cells and angiogenesis: decisions and indecisions. Cancer Metastasis Rev. 2008, 27: 31-40. 10.1007/s10555-007-9108-5.CrossRefPubMed
71.
Petersen F, Bock LA, Flad HD, Brandt E: Chondroitin sulfate proteoglycan on human neutrophils specifically binds platelet factor 4 and is involved in cell activation. J Immunol. 1998, 161: 4347-4355.PubMed
72.
Petersen F, Bock L, Flad HD, Brandt E: Platelet factor 4-induced neutrophil-endothelial cell interaction: involvement of mechanisms and functional consequences different from those elicited by interleukin-8. Blood. 1999, 94: 4020-4028.PubMed
73.
Han ZC, Lu M, Li J, Defard M, Boval B, Schlegel N, Caen JP: Platelet factor 4 and other CXC chemokines support the survival of normal hematopoietic cells and reduce the chemosensitivity of cells to cytotoxic agents. Blood. 1997, 89: 2328-2335.PubMed
74.
Clark-Lewis I, Dewald B, Geiser T, Moser B, Baggiolini M: Platelet factor 4 binds to interleukin 8 receptors and activates neutrophils when its N terminus is modified with Glu-Leu-Arg. Proc Natl Acad Sci USA. 1993, 90: 3574-3577. 10.1073/pnas.90.8.3574.PubMedCentralCrossRefPubMed
75.
von Hundelshausen P, Koenen RR, Sack M, Mause SF, Adriaens W, Proudfoot AE: Heterophilic interactions of platelet factor 4 and RANTES promote monocyte arrest on endothelium. Blood. 2005, 105: 924-930.CrossRefPubMed
76.
Pervushina O, Scheuerer B, Reiling N, Behnke L, Schröder JM, Kasper B, Brandt E: Platelet factor 4/CXCL4 induces phagocytosis and the generation of reactive oxygen metabolites in mononuclear phagocytes independently of Gi protein activation or intracellular calcium transients. J Immunol. 2004, 173: 2060-2067.CrossRefPubMed
77.
Scheuerer B, Ernst M, Dürrbaum-Landmann I, Fleischer J, Grage-Griebenow E: The CXC-chemokine platelet factor 4 promotes monocyte survival and induces monocyte differentiation into macrophages. Blood. 2000, 95: 1158-1166.PubMed
78.
Fricke I, Mitchell D, Petersen F, Böhle A, Bulfone-Paus S, Brandau S: Platelet factor 4 in conjunction with IL-4 directs differentiation of human monocytes into specialized antigenpresenting cells. FASEB J. 2004, 18: 1588-1590.PubMed
79.
Hayashi N, Chihara J, Kobayashi Y, Kakazu T, Kurachi D, Yamamoto T, Nakajima S: Effect of platelet-activating factor and platelet factor 4 on eosinophil adhesion. Int Arch Allergy Immunol. 1994, 104 (Suppl 1): 57-59.CrossRefPubMed
80.
Brindley LL, Sweet JM, Goetzl EJ: Stimulation of histamine release from human basophils by human platelet factor 4. J Clin Incest. 1983, 72: 1218-1223. 10.1172/JCI111077.CrossRef
81.
Marti F, Bertran E, Llucià M, Villén E, Peiró M, Garcia J, Rueda F: Platelet factor 4 induces human natural killer cells to synthesize and release interleukin-8. J Leukoc Biol. 2002, 72: 590-597.PubMed
82.
Fleischer J, Grage-Griebenow E, Kasper B, Heine H, Ernst M, Brandt E, Flad HD, Petersen F: Platelet factor 4 inhibits proliferation and cytokine release of activated human T cells. J Immunol. 2002, 169: 770-777.CrossRefPubMed
83.
Powell JA, Mousa SA: Neutrophil-activating protein-2- and interleukin-8-mediated angiogenesis. J Cell Biochem. 2007, 102: 412-420. 10.1002/jcb.21302.CrossRefPubMed
84.
Osselaer NV, Damme JV, Rampart M, Herman AG: Increased microvascular permeability in vivo in response to intradermal injection of neutrophil-activating protein (NAP-2) in rabbit skin. Am J Pathol. 1991, 13: 23-27.
85.
Malkowski MG, Lazar JB, Johnson PH, Edwards BF: The amino-terminal residues in the crystal structure of connective tissue activating peptide-III (des10) block the ELR chemotactic sequence. J Mol Biol. 1997, 226: 367-380.CrossRef
86.
Belman N, Bonnem EM, Harvey HA, Lipton A: Phase I trial of recombinant platelet factor 4 (rPF4) in patients with advanced colorectal carcinoma. Invest New Drugs. 1996, 14: 387-389.PubMed
87.
Kahn J, Ruiz R, Kerschmann R, Berger T, Ma R, Coleman R, Alford BL: A phase 1/2 study of recombinant plateler factor 4 (rPF4) in patients with AIDS related Kaposi’s sarcoma (KS) [abstract]. Proc Am Soc Clin Oncol. 1993, 12: s50-
88.
Northfelt DW, Robles R, Lang W, Wagner B, Kahn J, Bonnem E: Phase I/II study of intravenous (IV) recombinant platelet factor 4 (rPF4) in AIDS-related Kaposi‘s sarcoma (AIDS-KS) [abstract]. Proc Am Soc Clin Oncol. 1995, 14: s288-
89.
Hersh EM, Wiggins CE, Crook LI, Bonem EM: Phase I study of recombinant platelet factor 4 (rPF4) in patients with metastatic melanoma and renal cell carcinoma [abstract]. Proc Am Soc Clin Oncol. 1995, 14: s488-
90.
Dinapoli RP, Buckner JC, Rydberg CH, Mullan BP, Davis DH: Phase I-II study of localized injection of recombinant platelet factor 4 (rPF4) in patients (pts) with recurrent high-grade glioma [abstract]. Proc Am Soc Clin Oncol. 1995
91.
Cervi D, Yip TT, Bhattacharya N, Podust VN, Peterson J, Abou-Slaybi A, Naumov GN, Bender E, Almog N, Italiano JE, Folkman J, Klement GL: Platelet-associated PF-4 as a biomarker of early tumor growth. Blood. 2008, 111: 1201-1207.CrossRefPubMed
92.
Peterson JE, Zurakowski D, Italiano JE, Michel LV, Connors S, Oenick M, D‘Amato RJ, Klement GL, Folkman J: VEGF, PF4 and PDGF are elevated in platelets of colorectal cancer patients. Angiogenesis. 2012, 15: 265-273. 10.1007/s10456-012-9259-z.CrossRefPubMed
93.
Yee J, Sadar MD, Sin DD, Kuzyk M, Xing L, Kondra J, McWilliams A, Man SF, Lam S: Connective tissue-activating peptide III: a novel blood biomarker for early lung cancer detection. J Clin Oncol. 2009, 27: 2787-2792. 10.1200/JCO.2008.19.4233.PubMedCentralCrossRefPubMed
94.
Lee G, Gardner BK, Elashoff DA, Purcell CM, Sandha HS, Mao JT, Krysan K, Lee JM, Dubinett SM: Elevated levels of CXC chemokine connective tissue activating peptide (CTAP)-III in lung cancer patients. Am J Transl Res. 2011, 3: 226-233.PubMedCentralPubMed
95.
Grisaru D, Vlodavsky I, Prus D, Levavi H, Lessing JB, Eldor A, Friedmann Y: Connective tissue activating peptide III expression disappears progressively with increased dysplasia in human cervical epithelium. Gynecol Oncol. 2000, 79: 23-27. 10.1006/gyno.2000.5915.CrossRefPubMed
Metadata
Title
Role of platelet chemokines, PF-4 and CTAP-III, in cancer biology
Authors
Katerina Pilatova
Kristina Greplova
Regina Demlova
Beatrix Bencsikova
Giannoula Lakka Klement
Lenka Zdrazilova-Dubska
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Journal of Hematology & Oncology / Issue 1/2013
Electronic ISSN: 1756-8722
DOI
https://doi.org/10.1186/1756-8722-6-42

Other articles of this Issue 1/2013

Journal of Hematology & Oncology 1/2013 Go to the issue

Short report

Induction of long intergenic non-coding RNA HOTAIR in lung cancer cells by type I collagen

Research

Autoantibodies to Ezrin are an early sign of pancreatic cancer in humans and in genetically engineered mouse models

Research

Abnormal hematopoietic phenotypes in Pim kinase triple knockout mice

Research

Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and multicenter study

Rapid communication

A prospective phase II study of L-asparaginase- CHOP plus radiation in newly diagnosed extranodal NK/T-cell lymphoma, nasal type

Research

Erythropoietin is a JAK2 and ERK1/2 effector that can promote renal tumor cell proliferation under hypoxic conditions
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits